TriangleDISEASE & TREATMENT SETTING
Skin Cancer
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
Skin Cancer
- Source population
- Not part of this definition
- Disease extent
- Not part of this definition
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- derivation status
- source-attested
- derivation note
- Derived from NCI topic(s): Skin Cancer. Strongest NCIt resolution: exact. Entity-level scope; stage, biomarker and treatment line are not yet part of this definition.
- source wording
- Source null
3 more-specific settings
Study evidence for this setting
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy
Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Mel
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1
Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic
Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors
Source relationships and population-mapping limitations
- bindings
- release id
- clinical-indications-draft-1
- disease state id
- ds-skin-cancer
- binding id
- ncit-C2920
- source collection
- ncit-concept
- source key
- C2920
- source excerpt
- Source null
- match status
- exact
- match note
- Source null
- recorded at
- 2026-09-10T00:00:00Z
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice